

115TH CONGRESS  
2D SESSION

# H. R. 5776

To amend title XVIII to provide for Medicare coverage of certain services furnished by opioid treatment programs, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

MAY 11, 2018

Mr. NEAL (for himself, Mr. HOLDING, Mr. CARTWRIGHT, and Mr. TAYLOR) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To amend title XVIII to provide for Medicare coverage of certain services furnished by opioid treatment programs, and for other purposes.

1       *Be it enacted by the Senate and House of Representa-  
2 tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Medicare and Opioid  
5 Safe Treatment Act” or the “MOST Act”.

1   **SEC. 2. MEDICARE COVERAGE OF CERTAIN SERVICES FUR-**

2                   **NISHED BY OPIOID TREATMENT PROGRAMS.**

3               (a) COVERAGE.—Section 1861(s)(2) of the Social Se-

4      curity Act (42 U.S.C. 1395x(s)(2)) is amended—

5               (1) in subparagraph (FF), by striking at the

6      end “and”;

7               (2) in subparagraph (GG), by inserting at the

8      end “; and”; and

9               (3) by adding at the end the following new sub-

10     paragraph:

11               “(HH) opioid use disorder treatment serv-

12               ices (as defined in subsection (jjj)).”.

13       (b) OPIOID USE DISORDER TREATMENT SERVICES

14   AND OPIOID TREATMENT PROGRAM DEFINED.—Section

15   1861 of the Social Security Act is amended by adding at

16   the end the following new subsection:

17       “(jjj) OPIOID USE DISORDER TREATMENT SERV-

18   ICES; OPIOID TREATMENT PROGRAM.—

19       “(1) OPIOID USE DISORDER TREATMENT SERV-

20   ICES.—The term ‘opioid use disorder treatment serv-

21   ices’ means items and services that are furnished by

22   an opioid treatment program for the treatment of

23   opioid abuse disorder, including—

24       “(A) opioid agonist treatment medications

25       (including oral versions) that are approved by

26       the Food and Drug Administration under sec-

1           tion 505 of the Federal Food, Drug and Cos-  
2           metic Act for use in the treatment of opioid use  
3           disorder;

4           “(B) dispensing and administration of  
5           such medications, if applicable;

6           “(C) substance abuse counseling by a pro-  
7           fessional to the extent authorized under State  
8           law to furnish such services;

9           “(D) behavioral individual and group ther-  
10          apy with physicians or psychologists (or other  
11          mental health professionals to the extent au-  
12          thorized under State law);

13          “(E) toxicology testing; and

14          “(F) other items and services that the Sec-  
15          retary determines are appropriate.

16          “(2) OPIOID TREATMENT PROGRAM.—The term  
17          ‘opioid treatment program’ means an opioid treat-  
18          ment program (as defined in section 8.2 of title 42  
19          of the Code of Federal Regulations, or any successor  
20          regulation) that—

21          “(A) is enrolled under section 1866(j);

22          “(B) has in effect a certification by the  
23          Substance Abuse and Mental Health Services  
24          Administration for such a program;

1               “(C) is accredited by an accrediting body  
2               approved by the Substance Abuse and Mental  
3               Health Services Administration; and

4               “(D) meets such additional conditions as  
5               the Secretary may find necessary to ensure—

6                     “(i) the health and safety of individuals  
7               being furnished services under such  
8               program; and

9                     “(ii) the effective and efficient furnishing of such services.”.

11               (c) PAYMENT.—

12               (1) IN GENERAL.—Section 1833(a)(1) of the  
13               Social Security Act (42 U.S.C. 1395l(a)(1)) is  
14               amended—

15                     (A) by striking “and (BB)” and inserting  
16               “(BB)”; and

17                     (B) by inserting before the semicolon at  
18               the end the following “, and (CC) with respect  
19               to opioid use disorder treatment services fur-  
20               nished during an episode of care, the amount  
21               paid shall be equal to the amount payable in ac-  
22               cordance with section 1834(w) less any copay-  
23               ment required as specified by the Secretary”.

24               (2) PAYMENT DETERMINATION.—Section 1834  
25               of the Social Security Act (42 U.S.C. 1395m) is

1       amended by adding at the end the following new  
2       subsection:

3       “(w) OPIOID USE DISORDER TREATMENT SERV-  
4       ICES.—

5           “(1) IN GENERAL.—The Secretary shall pay to  
6       an opioid treatment program (as defined in para-  
7       graph (2) of section 1861(jjj)) an amount that is  
8       equal to 100 percent of a bundled payment under  
9       this part for opioid use disorder treatment services  
10      (as defined in paragraph (1) of such section) that  
11      are furnished by such program to an individual dur-  
12      ing an episode of care (as defined by the Secretary)  
13      beginning on or after January 1, 2020. The Sec-  
14      retary shall ensure that no duplicative payments are  
15      made under this part or part D to a physician, prac-  
16      titioner, or pharmacy for items and services fur-  
17      nished by an opioid treatment program.

18           “(2) CONSIDERATIONS.—The Secretary may  
19      implement this subsection through one or more bun-  
20      dles based on the type of medication provided (such  
21      as buprenorphine, methadone, naltrexone, or a new  
22      innovative drug), the frequency of services, the scope  
23      of services furnished, characteristics of the individ-  
24      uals furnished such services, or other factors as the  
25      Secretary determine appropriate. In developing such

1       bundles, the Secretary may consider payment rates  
2       paid to opioid treatment programs for comparable  
3       services under State plans under title XIX, under  
4       the TRICARE program under chapter 55 of title 10  
5       of the United States Code, or by other health care  
6       payers.

7               “(3) ANNUAL UPDATES.—The Secretary shall  
8       provide an update each year to the bundled payment  
9       amounts under this subsection.”.

10          (d) INCLUDING OPIOID TREATMENT PROGRAMS AS  
11 MEDICARE PROVIDERS.—Section 1866(e) of the Social  
12 Security Act (42 U.S.C. 1395cc(e)) is amended—

13               (1) in paragraph (2), by striking at the end  
14       “and”;

15               (2) in paragraph (3), by striking the period at  
16       the end and inserting “; and”; and

17               (3) by adding at the end the following new  
18       paragraph:

19               “(3) opioid treatment programs (as defined in  
20       paragraph (2) of section 1861(jjj)), but only with re-  
21       spect to the furnishing of opioid treatment program  
22       services (as defined in paragraph (1) of such sec-  
23       tion).”.

1     **SEC. 3. REVIEW AND ADJUSTMENT OF PAYMENTS UNDER**  
2                 **THE MEDICARE OUTPATIENT PROSPECTIVE**  
3                 **PAYMENT SYSTEM TO AVOID FINANCIAL IN-**  
4                 **CENTIVES TO USE OPIOIDS INSTEAD OF NON-**  
5                 **OPIOID ALTERNATIVE TREATMENTS.**

6     (a) **OUTPATIENT PROSPECTIVE PAYMENT SYS-**  
7     **TEM.**—Section 1833(t) of the Social Security Act (42  
8     U.S.C. 1395l(t)) is amended by adding at the end the fol-  
9     lowing new paragraph:

10                 “(22) **REVIEW AND REVISIONS OF PAYMENTS**  
11                 **FOR NON-OPIOID ALTERNATIVE TREATMENTS.**—

12                 “(A) **IN GENERAL.**—With respect to pay-  
13     ments made under this subsection for covered  
14     OPD services (or groups of services), including  
15     covered OPD services assigned to a comprehen-  
16     sive ambulatory payment classification, the Sec-  
17     retary—

18                 “(i) shall, as soon as practicable, con-  
19     duct a review (part of which may include  
20     a request for information) of payments for  
21     opioids and evidence-based non-opioid al-  
22     ternatives for pain management (including  
23     drugs and devices, nerve blocks, surgical  
24     injections, and neuromodulation) with a  
25     goal of ensuring that there are not finan-

1           cial incentives to use opioids instead of  
2           non-opioid alternatives;

3               “(ii) may, as the Secretary determines  
4               appropriate, conduct subsequent reviews of  
5               such payments; and

6               “(iii) shall consider the extent to  
7               which revisions under this subsection to  
8               such payments (such as the creation of ad-  
9               ditional groups of covered OPD services to  
10              classify separately those procedures that  
11              utilize opioids and non-opioid alternatives  
12              for pain management) would reduce pay-  
13              ment incentives to use opioids instead of  
14              non-opioid alternatives for pain manage-  
15              ment.

16           “(B) PRIORITY.—In conducting the review  
17           under clause (i) of subparagraph (A) and con-  
18           sidering revisions under clause (iii) of such sub-  
19           paragraph, the Secretary shall focus on covered  
20           OPD services (or groups of services) assigned  
21           to a comprehensive ambulatory payment classi-  
22           fication, ambulatory payment classifications  
23           that primarily include surgical services, and  
24           other services determined by the Secretary

1                   which generally involve treatment for pain man-  
2                   agement.

3                 “(C) REVISIONS.—If the Secretary identi-  
4                 fies revisions to payments pursuant to subpara-  
5                 graph (A)(iii), the Secretary shall, as deter-  
6                 mined appropriate, begin making such revisions  
7                 for services furnished on or after January 1,  
8                 2020. Revisions under the previous sentence  
9                 shall be treated as adjustments for purposes of  
10                application of paragraph (9)(B).

11                “(D) RULES OF CONSTRUCTION.—Nothing  
12                in this paragraph shall be construed to preclude  
13                the Secretary—

14                   “(i) from conducting a demonstration  
15                 before making the revisions described in  
16                 subparagraph (C); or

17                   “(ii) prior to implementation of this  
18                 paragraph, from changing payments under  
19                 this subsection for covered OPD services  
20                 (or groups of services) which include  
21                 opioids or non-opioid alternatives for pain  
22                 management.”.

23                (b) AMBULATORY SURGICAL CENTERS.—Section  
24                1833(i) of the Social Security Act (42 U.S.C. 1395l(i))

1 is amended by adding at the end the following new para-  
2 graph:

3           “(8) The Secretary shall apply the provisions of  
4 paragraph (22) of section 1833(t), including the sec-  
5 ond sentence of subparagraph (C) of such para-  
6 graph, to payment for services under this subsection  
7 in an appropriate manner (as determined by the  
8 Secretary).”.

9 **SEC. 4. EXPANDING ACCESS UNDER THE MEDICARE PRO-**

10           **GRAM TO ADDICTION TREATMENT IN FEDER-**  
11           **ALLY QUALIFIED HEALTH CENTERS AND**  
12           **RURAL HEALTH CLINICS.**

13       (a) **FEDERALLY QUALIFIED HEALTH CENTERS.—**  
14 Section 1834(o) of the Social Security Act (42 U.S.C.  
15 1395m(o)) is amended by adding at the end the following  
16 new paragraph:

17           “(3) **ADDITIONAL PAYMENTS FOR CERTAIN**  
18 **FQHCS WITH PRACTITIONERS RECEIVING DATA 2000**  
19 **CERTIFICATION.—**

20           “(A) **IN GENERAL.**—In the case of a Fed-  
21 erally qualified health center with respect to  
22 which, beginning January 1, 2019, Federally-  
23 qualified health center services (as defined in  
24 section 1861(aa)(3)) are furnished by a health  
25 care practitioner who first receives on or after

such date a registration or waiver under section 303(g) of the Controlled Substances Act to prescribe or dispense methadone, buprenorphine, or suboxone for the purpose of maintenance or detoxification treatment, the Secretary shall, subject to availability of funds under subparagraph (B), make a payment (in accordance with such timing, method, and procedures as specified by the Secretary) to such Federally qualified health center in an amount determined by the Secretary, based on an approximation of the cost to receive training for purposes of such registration or waiver, as applicable. For purposes of the previous sentence, a Federally-qualified health center shall apply for a payment described in such sentence at such time and in such manner as specified by the Secretary and may apply for such a payment for each practitioner furnishing such services at such center who is described in such sentence.

“(B) FUNDING.—For purposes of making payments under this paragraph, there are appropriated, out of amounts in the Treasury not otherwise appropriated, \$6,000,000, which shall remain available until expended.”.

1       (b) RURAL HEALTH CLINIC.—Section 1833 of the  
2 Social Security Act (42 U.S.C. 1395l) is amended—

3                 (1) by redesignating the subsection (z) relating  
4 to medical review of spinal subluxation services as  
5 subsection (aa); and

6                 (2) by adding at the end the following new sub-  
7 section:

8                 “(bb) ADDITIONAL PAYMENTS FOR CERTAIN RURAL  
9 HEALTH CLINICS WITH PRACTITIONERS RECEIVING  
10 DATA 2000 CERTIFICATION.—

11                 “(1) IN GENERAL.—In the case of a rural  
12 health clinic with respect to which, beginning Janu-  
13 ary 1, 2019, rural health clinic services (as defined  
14 in section 1861(aa)(1)) are furnished by a health  
15 care practitioner who first receives on or after such  
16 date a registration or waiver under section 303(g) of  
17 the Controlled Substances Act to prescribe or dis-  
18 pense methadone, buprenorphine, or suboxone for  
19 the purpose of maintenance or detoxification treat-  
20 ment, the Secretary shall, subject to availability of  
21 funds under subparagraph (B), make a payment (in  
22 accordance with such timing, method, and proce-  
23 dures as specified by the Secretary) to such rural  
24 health clinic in an amount determined by the Sec-  
25 retary, based on an approximation of the cost to re-

1 receive training for purposes of such registration or  
2 waiver, as applicable. For purposes of the previous  
3 sentence, a rural health clinic shall apply for a pay-  
4 ment described in such sentence at such time and in  
5 such manner as specified by the Secretary and may  
6 apply for such a payment for each practitioner fur-  
7 nishing such services at such clinic who is described  
8 in such sentence.

9               “(2) FUNDING.—For purposes of making pay-  
10      ments under this subsection, there are appropriated,  
11      out of amounts in the Treasury not otherwise appro-  
12      priated, \$2,000,000, which shall remain available  
13      until expended.”.

14 SEC. 5. STUDYING THE AVAILABILITY OF SUPPLEMENTAL  
15 BENEFITS DESIGNED TO TREAT OR PREVENT  
16 SUBSTANCE USE DISORDERS UNDER MEDI-  
17 CARE ADVANTAGE PLANS.

(a) IN GENERAL.—Not later than 2 years after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the “Secretary”) shall submit to Congress a report on the availability of supplemental health care benefits (as described in section 1852(a)(3)(A) of the Social Security Act (42 U.S.C. 1395w–22(a)(3)(A))) designed to treat or prevent substance use disorders under Medicare Advantage

1 plans offered under part C of title XVIII of such Act. Such  
2 report shall include the analysis described in subsection  
3 (c) and any differences in the availability of such benefits  
4 under specialized MA plans for special needs individuals  
5 (as defined in section 1859(b)(6) of such Act (42 U.S.C.  
6 1395w–28(b)(6))) offered to individuals entitled to med-  
7 ical assistance under title XIX of such Act and other such  
8 Medicare Advantage plans.

9 (b) CONSULTATION.—The Secretary shall develop the  
10 report described in subsection (a) in consultation with rel-  
11 evant stakeholders, including—

12 (1) individuals entitled to benefits under part A  
13 or enrolled under part B of title XVIII of the Social  
14 Security Act;

15 (2) entities who advocate on behalf of such indi-  
16 viduals;

17 (3) Medicare Advantage organizations;

18 (4) pharmacy benefit managers; and

19 (5) providers of services and suppliers (as such  
20 terms are defined in section 1861 of such Act (42  
21 U.S.C. 1395x)).

22 (c) CONTENTS.—The report described in subsection  
23 (a) shall include an analysis on the following:

1                         (1) The extent to which plans described in such  
2 subsection offer supplemental health care benefits  
3 relating to coverage of—

4                             (A) medication-assisted treatments for  
5 opioid use, substance use disorder counseling,  
6 peer recovery support services, or other forms  
7 of substance use disorder treatments (whether  
8 furnished in an inpatient or outpatient setting);  
9 and

10                         (B) non-opioid alternatives for the treat-  
11 ment of pain.

12                         (2) Challenges associated with such plans offer-  
13 ing supplemental health care benefits relating to cov-  
14 erage of items and services described in subpara-  
15 graph (A) or (B) of paragraph (1).

16                         (3) The impact, if any, of increasing the appli-  
17 cable rebate percentage determined under section  
18 1854(b)(1)(C) of the Social Security Act (42 U.S.C.  
19 1395w-24(b)(1)(C)) for plans offering such benefits  
20 relating to such coverage would have on the avail-  
21 ability of such benefits relating to such coverage of-  
22 fered under Medicare Advantage plans.

23                         (4) Potential ways to improve upon such cov-  
24 erage or to incentivize such plans to offer additional

1 supplemental health care benefits relating to such  
2 coverage.

3 SEC. 6. CLINICAL PSYCHOLOGIST SERVICES MODELS  
4 UNDER THE CENTER FOR MEDICARE AND  
5 MEDICAID INNOVATION; GAO STUDY AND RE-  
6 PORT.

7       (a) CMI MODELS.—Section 1115A(b)(2)(B) of the  
8 Social Security Act (42 U.S.C. 1315a(b)(2)(B)) is amend-  
9 ed by adding at the end the following new clauses:

“(xxv) Supporting ways to familiarize individuals with the availability of coverage under part B of title XVIII for qualified psychologist services (as defined in section 1861(ii)).

15                     “(xxvi) Exploring ways to avoid un-  
16                     necessary hospitalizations or emergency de-  
17                     partment visits for mental and behavioral  
18                     health services (such as for treating de-  
19                     pression) through use of a 24-hour, 7-day  
20                     a week help line that may inform individ-  
21                     uals about the availability of treatment op-  
22                     tions, including the availability of qualified  
23                     psychologist services (as defined in section  
24                     1861(ii)).”.

1       (b) GAO STUDY AND REPORT.—Not later than 18  
2 months after the date of the enactment of this Act, the  
3 Comptroller General of the United States shall conduct  
4 a study, and submit to Congress a report, on mental and  
5 behavioral health services under the Medicare program  
6 under title XVIII of the Social Security Act, including an  
7 examination of the following:

8              (1) Information about services furnished by  
9 psychiatrists, clinical psychologists, and other profes-  
10 sionals.

11              (2) Information about ways that Medicare bene-  
12 ficiaries familiarize themselves about the availability  
13 of Medicare payment for qualified psychologist serv-  
14 ices (as defined in section 1861(ii) of the Social Se-  
15 curity Act (42 U.S.C. 1395x(ii))) and ways that the  
16 provision of such information could be improved.

17 **SEC. 7. PAIN MANAGEMENT STUDY.**

18       (a) IN GENERAL.—Not later than 1 year after the  
19 date of enactment of this Act, the Secretary of Health and  
20 Human Services (referred to in this section as the “Sec-  
21 retary”) shall conduct a study and submit to the Com-  
22 mittee on Ways and Means and the Committee on Energy  
23 and Commerce of the House of Representatives and the  
24 Committee on Finance of the Senate a report containing  
25 recommendations on whether and how payment to pro-

1 viders and suppliers of services and coverage related to  
2 the use of multi-disciplinary, evidence-based, non-opioid  
3 treatments for acute and chronic pain management for in-  
4 dividuals entitled to benefits under part A or enrolled  
5 under part B of title XVIII of the Social Security Act  
6 should be revised. The Secretary shall make such report  
7 available on the public website of the Centers for Medicare  
8 & Medicaid Services.

9                 (b) CONSULTATION.—In developing the report de-  
10 scribed in subsection (a), the Secretary shall consult  
11 with—

12                         (1) relevant agencies within the Department of  
13 Health and Human Services;

14                         (2) licensed and practicing osteopathic and  
15 allopathic physicians, behavioral health practitioners,  
16 physician assistants, nurse practitioners, dentists,  
17 pharmacists, and other providers of health services;

18                         (3) providers and suppliers of services (as such  
19 terms are defined in section 1861 of the Social Secu-  
20 rity Act (42 U.S.C. 1395x));

21                         (4) substance abuse and mental health profes-  
22 sional organizations;

23                         (5) pain management professional organizations  
24 and advocacy entities, including individuals who per-  
25 sonally suffer chronic pain;

1                         (6) medical professional organizations and med-  
2                         ical specialty organizations;

3                         (7) licensed health care providers who furnish  
4                         alternative pain management services;

5                         (8) organizations with expertise in the develop-  
6                         ment of innovative medical technologies for pain  
7                         management;

8                         (9) beneficiary advocacy organizations; and

9                         (10) other organizations with expertise in the  
10                         assessment, diagnosis, treatment, and management  
11                         of pain, as determined appropriate by the Secretary.

12                         (c) CONTENTS.—The report described in subsection

13                         (a) shall include the following:

14                         (1) The recommendations described in sub-  
15                         section (d).

16                         (2) The impact analysis described in subsection  
17                         (e).

18                         (3) An assessment of pain management guid-  
19                         ance published by the Federal Government that may  
20                         be relevant to coverage determinations or other cov-  
21                         erage requirements under title XVIII of the Social  
22                         Security Act. Such assessment shall consider incor-  
23                         porating into such guidance relevant elements of the  
24                         “Va/DoD Clinical Practice Guideline for Opioid  
25                         Therapy for Chronic Pain” published in February

1       2017 by the Department of Veterans Affairs and  
2       Department of Defense, including adoption of ele-  
3       ments of the Department of Defense and Veterans  
4       Administration pain rating scale.

5                 (4) An evaluation of the following:

6                     (A) Barriers inhibiting individuals entitled  
7        to benefits under part A or enrolled under part  
8        B of such title from accessing treatments and  
9        technologies described in subparagraphs (A)  
10      through (F) of paragraph (6).

11                   (B) Potential legislative and administrative  
12      changes under such title to improve individuals'  
13      access to items and services currently covered  
14      under such title and used for the treatment of  
15      pain, such as cognitive behavioral interventions,  
16      physical therapy, occupational therapy, physical  
17      medicine, biofeedback therapy, and chiropractic  
18      therapy, and other pain treatments services fur-  
19      nished in a hospital or post-acute care setting.

20                   (C) Costs and benefits associated with po-  
21      tential expansion of coverage under such title to  
22      include items and services not covered under  
23      such title that may be used for the treatment  
24      of pain, such as acupuncture, therapeutic mas-

1           sage, and items and services furnished by inte-  
2           grated pain management programs.

3           (5) An analysis on payment and coverage under  
4           title XVIII of the Social Security Act with respect  
5           to the following:

6               (A) Evidence-based treatments and tech-  
7               nologies for chronic or acute pain, including  
8               such treatments that are covered, not covered,  
9               or have limited coverage under such title.

10              (B) Evidence-based treatments and tech-  
11               nologies that monitor substance use withdrawal  
12               and prevent overdoses of opioids.

13              (C) Evidence-based treatments and tech-  
14               nologies that treat substance use disorders.

15              (D) Items and services furnished by practi-  
16               tioners through a multi-disciplinary treatment  
17               model for pain management, including the pa-  
18               tient-centered medical home.

19              (E) Medical devices, non-opioid based  
20               drugs, and other therapies (including inter-  
21               ventional and integrative pain therapies) ap-  
22               proved or cleared by the Food and Drug Ad-  
23               ministration for the treatment of pain.

24              (F) Items and services furnished to bene-  
25               ficiaries with psychiatric disorders, substance

1           use disorders, or who are at risk of suicide, or  
2           have comorbidities and require consultation or  
3           management of pain with one or more special-  
4           ists in pain management, mental health, or ad-  
5           diction treatment.

6         (d) RECOMMENDATIONS.—The recommendations de-  
7         scribed in this subsection are, with respect to individuals  
8         entitled to benefits under part A or enrolled under part  
9         B of title XVIII of the Social Security Act, legislative and  
10        administrative recommendations on the following:

11           (1) Options for additional coverage of pain  
12           management therapies without the use of opioids, in-  
13           cluding interventional pain therapies, and options to  
14           augment opioid therapy with other clinical and com-  
15           plementary, integrative health services to minimize  
16           the risk of substance use disorder, including in a  
17           hospital setting.

18           (2) Options for coverage and payment modifica-  
19           tions of medical devices and non-opioid based phar-  
20           macological and non-pharmacological therapies (in-  
21           cluding interventional and integrative pain thera-  
22           pies) approved or cleared by the Food and Drug Ad-  
23           ministration for the treatment of pain as an alter-  
24           native or augment to opioid therapy.

1                             (3) Treatment strategies for beneficiaries with  
2 psychiatric disorders, substance use disorders, or  
3 who are at risk of suicide, and treatment strategies  
4 to address health disparities related to opioid use  
5 and opioid abuse treatment.

6                             (4) Treatment strategies for beneficiaries with  
7 comorbidities who require a consultation or co-  
8 management of pain with one or more specialists in  
9 pain management, mental health, or addiction treat-  
10 ment, including in a hospital setting.

11                            (5) Coadministration of opioids and other  
12 drugs, particularly benzodiazepines.

13                           (6) Appropriate case management for bene-  
14 ficiaries who transition between inpatient and out-  
15 patient hospital settings, or between opioid therapy  
16 to non-opioid therapy, which may include the use of  
17 care transition plans.

18                           (7) Outreach activities designed to educate pro-  
19 viders of services and suppliers under the Medicare  
20 program and individuals entitled to benefits under  
21 part A or under part B of such title on alternative,  
22 non-opioid therapies to manage and treat acute and  
23 chronic pain.

24                           (8) Creation of a beneficiary education tool on  
25 alternatives to opioids for chronic pain management.

1       (e) IMPACT ANALYSIS.—The impact analysis de-  
2 scribed in this subsection consists of an analysis of any  
3 potential effects implementing the recommendations de-  
4 scribed in subsection (d) would have—

5              (1) on expenditures under the Medicare pro-  
6 gram; and

7              (2) on preventing or reducing opioid addiction  
8 for individuals receiving benefits under the Medicare  
9 program.

○